Sylvie Ryckebusch
Corporate Officer/Principal chez BIOINVENT INTERNATIONAL AB
Fortune : 28 411 $ au 31/03/2024
Profil
Sylvie Ryckebusch currently works at Domain Therapeutics SA, as Non-Executive Director and BioInvent International AB, as Chief Business Officer from 2022.
Dr. Ryckebusch received her doctorate degree from California Institute of Technology and undergraduate degree from the University of Maryland.
Détentions connues dans des sociétés publiques
Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
---|---|---|---|---|
31/12/2022 | 17 870 ( 0,03% ) | 28 411 $ | 31/03/2024 |
Postes actifs de Sylvie Ryckebusch
Sociétés | Poste | Début |
---|---|---|
BIOINVENT INTERNATIONAL AB | Corporate Officer/Principal | 09/06/2022 |
Domain Therapeutics SA
Domain Therapeutics SA BiotechnologyHealth Technology Domain Therapeutics SA discovers and develops drug candidates targeting G-protein coupled receptors (GPCR) in all major therapeutic fields. The firm?s products include technologies, such as DTect-All and BioSens-All. Its services encompass allosteric modulators identification, biased ligands selection, orphan and historically intractable GPCRs address and high throughput screening campaign. The company was founded by Maurice Isra?l, Pierre Potier, Bernard Jacques Alex Gilly, Yves Dunant and Pascal Neuville in 2008 and is headquartered in Illkirch-Graffenstaden, France. | Director/Board Member | - |
Formation de Sylvie Ryckebusch
California Institute of Technology | Doctorate Degree |
University of Maryland | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
Sociétés cotées | 1 |
---|---|
BIOINVENT INTERNATIONAL AB | Health Technology |
Entreprise privées | 1 |
---|---|
Domain Therapeutics SA
Domain Therapeutics SA BiotechnologyHealth Technology Domain Therapeutics SA discovers and develops drug candidates targeting G-protein coupled receptors (GPCR) in all major therapeutic fields. The firm?s products include technologies, such as DTect-All and BioSens-All. Its services encompass allosteric modulators identification, biased ligands selection, orphan and historically intractable GPCRs address and high throughput screening campaign. The company was founded by Maurice Isra?l, Pierre Potier, Bernard Jacques Alex Gilly, Yves Dunant and Pascal Neuville in 2008 and is headquartered in Illkirch-Graffenstaden, France. | Health Technology |